Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure ...

The trial showed that patients taking this novel therapy, an oral soluble guanylate cyclase stimulator, were 10% less likely to experience the primary outcome—a composite of death from ...

Nine out of 10 hospitalized patients who have heart failure with reduced ejection fraction (HFrEF) may be potential candidates for the novel agent vericiguat (Merck Sharp & Dohme/Bayer) to lower their ...

An investigational drug vericiguat offers new hope for patients with worsening heart failure, reports a new study. Patients with worsening heart failure and reduced ejection fraction who received the ...

Please provide your email address to receive an email when new articles are posted on . Vericiguat, a novel oral soluble guanylate cyclase stimulator, reduced the incidence of HF hospitalization or CV ...

Vericiguat Reduced the Risk of Heart Failure Hospitalization or Cardiovascular Death in Patients with Worsening Chronic Heart Failure with Reduced Ejection Fraction, Compared to Placebo When Added to ...

1-in-3 men have some form of cardiovascular disease, according to the American Heart Association. An estimated 2.8 million men experience stroke each year and hypertension is common in younger men.

Researchers presented new data on patient characteristics and outcomes seen in the VICTORIA trial of vericiguat. New data from the Vericiguat Global Study in Subjects With Heart Failure with Reduced ...

Madrid, Spain – 30 August 2025: Vericiguat reduced the risk of cardiovascular mortality, heart failure (HF) hospitalisations and all-cause mortality across a broad range of patients with HF and ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the VICTORIA trial, a Phase 3 study evaluating ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO, Fla. — Vericiguat, a novel soluble guanylate cyclase stimulator, did not significantly influence ...

The investigational oral soluble guanylate-cyclase (sGC) stimulator vericiguat (Bayer/Merck), under development for treating worsening chronic heart failure (HF), met the primary efficacy endpoint in ...